Article Search
검색
검색 팝업 닫기

All Menu

Metrics

Help

  • 1. Aims and Scope

    Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE

  • 2. Editorial Board

    Editor-in-Chief + MORE

    Editor-in-Chief
    Yong Chan Lee Professor of Medicine
    Director, Gastrointestinal Research Laboratory
    Veterans Affairs Medical Center, Univ. California San Francisco
    San Francisco, USA

    Deputy Editor

    Deputy Editor
    Jong Pil Im Seoul National University College of Medicine, Seoul, Korea
    Robert S. Bresalier University of Texas M. D. Anderson Cancer Center, Houston, USA
    Steven H. Itzkowitz Mount Sinai Medical Center, NY, USA
  • 3. Editorial Office
    + MORE
  • 4. Articles
  • 5. Instructions for Authors
  • 6. File Download (PDF version)
  • 7. Ethical Standards
  • 8. Peer Review

    All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
    The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.

    The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.

Search

Search

Year

to

Article Type

Review

Split Viewer

Management of Antiviral Resistance in Chronic Hepatitis B

Young-Suk Lim

Author Info +

Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Correspondence to: Young-Suk Lim, Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea, Tel: +82-2-3010-5933, Fax: +82-2-485-5782, E-mail: limys@amc.seoul.kr

Received: November 2, 2015; Accepted: January 17, 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gut Liver 2017;11(2):189-195. https://doi.org/10.5009/gnl15562

Published online February 13, 2017, Published date March 15, 2017

Copyright © Gut and Liver.

Abstract

Go to

The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression. Hepatitis B surface antigen (HBsAg) seroclearance or seroconversion is regarded as an optimal endpoint to discontinue treatment. However, HBsAg seroclearance occurs very rarely with nucleos(t)ide analog (NUC) treatment, and long-term, almost indefinite, NUC treatment is required for the majority of patients. In patients with drug-resistant hepatitis B virus (HBV), a combination of tenofovir disoproxil fumarate (TDF) and entecavir (ETV), which is currently regarded as the strongest combination therapy against HBV, would be potentially safe to prevent the emergence of additional HBV resistance mutations. However, long-term tolerance data are lacking, and cost may be an issue for combination therapies. Several recent, well-designed, randomized controlled trials have shown that TDF mono-therapy provides similar antiviral efficacy compared with the combination of TDF and ETV. Furthermore, no additional HBV resistance mutations emerged during TDF monotherapy for up to 96 weeks. Considering a comparable antiviral efficacy, extremely low risk of TDF-resistance, lower cost, and better safety potential, TDF monotherapy would be a reasonable choice for the treatment of drug-resistant patients with CHB.

Keywords: Adefovir, Entecavir, Lamivudine, Monotherapy, Tenofovir

INTRODUCTION

Go to

High serum hepatitis B virus (HBV) DNA levels are an independent risk factor for disease progression to cirrhosis and hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB).1,2 By contrast, reducing HBV DNA concentrations to very low or undetectable levels through long-term nucleos(t)ide analogue (NUC) therapy is associated with reduced risk of mortality and/or HCC.3–11

Over the past two decades, treatment of CHB has greatly improved with the availability of NUCs, including lamivudine (LAM), adefovir (ADV), entecavir (ETV), telbivudine, and tenofovir, which target particular sites of viral polymerases.12–14 Particularly, with the availability of potent NUCs, such as tenofovir disoproxil fumarate (TDF) and ETV, suppression of serum HBV DNA to levels undetectable by polymerase chain reaction assays is achievable in most NUC treatment-naïve patients in the absence of drug-resistant HBV mutants (Fig. 1).15,16 However, many patients worldwide have developed drug-resistance from the widespread use of less potent NUCs, such as LAM or ADV, which have a low genetic barrier to resistance. Patients with persistent drug-resistant HBV viremia are more likely to suffer hepatitis flares, disease progression, and to die than those without drug-resistant HBV.3,6

MECHANISM OF ANTIVIRAL DRUG RESISTANCE

Go to

Nucleoside- and nucleotide-analogues selectively target HBV DNA polymerase, resulting in premature chain termination of viral replication. Drug-resistant strains of HBV have signature mutations in the reverse transcriptase domains of the viral polymerase gene (Table 1). Resistance mutations alter the interaction between HBV polymerase and drug, which interfere the inhibitory effect of drug on viral polymerase. After emergence of primary resistance mutations, compensatory mutations that restore replication capacity may arise (Fig. 2), as well as secondary resistance mutations that increase drug resistance when they accumulate on the same viral genome.

Once antiviral-resistant HBV mutants have been selected, they are persistently retained in the virus population even if treatment is stopped, and exerts cross-resistance to the next sequential monotherapy (Fig. 2).14,17,18 For example, ADV-resistant mutations emerge more frequently during ADV monotherapy in LAM-resistant than in treatment-naïve patients.19–21 The rate of ETV resistance increases up to 51% after 5 years of ETV treatment in patients with LAM-resistant HBV, which is in striking contrast to a 1.2% resistance rate in NUC-naïve patients.22,23 Thus, combination therapy with a nucleoside analogue (LAM, telbivudine, or ETV) and a nucleotide analogue (ADV or TDF) has generally been recommended for the treatment of patients harboring drug-resistant HBV.14,24–26 However, several recent studies including ours have suggested that TDF monotherapy is efficacious in patients with LAM-resistant, ETV-resistant, or ADV-resistant HBV.27–32

MANAGEMENT OF RESISTANCE TO LAMIVUDINE

Go to

For LAM-resistant patients, a combination of ADV and LAM showed no greater antiviral efficacy than ADV monotherapy.33 Nonetheless, ADV and LAM combination therapy had been recommended for these patients to prevent additional emergence of ADV-resistant HBV mutants.14,20,24,25,34–36

However, the situation is clearly different if TDF, that has about 30 times higher anti-HBV potency than ADV, is used instead of ADV. Treatment responses to TDF and LAM combination therapy would likely be mediated by TDF alone, since LAM may have no or minimal antiviral efficacy in the presence of LAM-resistant HBV mutants. With this combination, continued LAM treatment would likely only help prevent the development of TDF-resistance mutations, rather than increasing antiviral potency. Therefore, if there is minimal risk of TDF-resistance,16,37 the addition of LAM to TDF would theoretically provide little benefit. The hypothesis was actually proven by a recent randomized double-blind controlled trial.29 The study showed that TDF monotherapy was highly efficacious in patients with LAM-resistant HBV, which was comparable to the combination of TDF and emtricitabine, without emergence of additional resistance mutations to TDF throughout 96 weeks of treatment (Fig. 3).29,37 Entricitabine is an unapproved nucleoside analogue which has very similar anti-HBV potency and barrier to resistance development as LAM. Thus, the study results indicate that adding LAM to TDF would not provide additional antiviral benefit, and that TDF monotherapy is safe and efficacious to patients with LAM-resistant HBV.

MANAGEMENT OF RESISTANCE TO LAM AND ETV

Go to

In patients with pre-existing LAM-resistance, the rate of ETV resistance increases up to 51% after 5 years of ETV treatment, which is in striking contrast to a 1.2% resistance rate in NUC-naïve patients.22,23 In addition, ETV monotherapy was suboptimal in suppressing HBV replication in patients with LAM-resistant HBV, with an unacceptably low virologic response rate (22%) seen at 12 months.38,39 This difference is because the ETV resistance barrier is lowered by the initial selection of the LAM-resistant HBV mutation, rtM204V/I.40In vitro studies have shown that susceptibility to ETV is decreases by 10- to 250-fold when one of the ETV resistance-associated substitutions at rtT184, rtS202, or rtM250 is present in combination with rtM204V/I, and by >500-fold when two or more of these mutations are present.22,40

In vitro studies suggest that ETV-resistant HBV mutants are susceptible to TDF.17,41 These in vitro studies showed that HBV strains harboring the ETV resistance-associated substitutions, rtM204V/I, rtT184, rtS202, and/or rtM250, exhibit no cross-resistance to tenofovir.17,41 Several case reports and retrospective cohort studies also showed the clinical efficacy of TDF in ETV-resistant or ETV-refractory patients.42–44

In our recent multicenter randomized trial, patients who had HBV with ETV resistance-associated mutations and serum HBV DNA concentrations >60 IU/mL were randomized to receive TDF (300 mg/day) monotherapy (n=45) or TDF and ETV (1 mg/day) combination therapy (n=45). At week 48, the proportion of patients with HBV DNA <15 IU/mL, the primary efficacy endpoint, was not significantly different between the TDF and TDF+ETV groups (71% vs 73%, p=0.81). The proportion of patients who achieved HBV DNA levels <60 IU/mL at week 48 was 82% and 89% for the TDF and TDF+ETV groups, respectively (p=0.55) (Fig. 4). The mean change in HBV DNA levels from baseline was not significantly different between groups (−3.65 log10 IU/mL vs −3.77 log10 IU/mL, p=0.69). Virologic breakthrough occurred in one patient on TDF, which was attributed to poor drug adherence. At week 48, six and three patients in the TDF and TDF+ETV groups, respectively, retained their baseline resistance mutations (p>0.99). None developed additional resistance mutations. Safety profiles were comparable in the two groups. The rate of virologic response by TDF monotherapy in our study was similar with that of a recent single arm trial with TDF+ETV in CHB patients with previous NUC treatment failure (85% had HBV DNA <50 IU/mL at week 96).45 These results support the view that TDF monotherapy may be a treatment option for patients with ETV-resistant HBV.

MANAGEMENT OF RESISTANCE TO LAM AND ADV

Go to

In vitro clonal analyses showed that multidrug-resistance mutations usually reside in the same viral genome,18,46 and antiviral sensitivities revealed that replicating clones with LAM- and ADV-associated mutations had >50-fold reduced susceptibility to combination of LAM and ADV.47,48 In fact, our previous cohort study demonstrated that, in patients with HBV resistant to LAM and ADV, combination therapy with these two drugs was not effective and was even inferior to ETV monotherapy in suppressing HBV DNA.49 However, the response to ETV monotherapy was not optimal. We demonstrated that ETV was far less effective in patients refractory to both LAM and ADV than in those with LAM mono-resistance.50

In vitro studies have shown that HBV strains expressing the ADV resistance-associated substitutions, rtA181T/V and/or rtN236T, demonstrate reduced susceptibility to tenofovir, ranging from 2.9- to 10-fold of that of the wild-type virus.46,51–53 Several cohort studies also showed reduced TDF efficacy in patients with ADV-resistant HBV.30,54 An European cohort study showed that, the probability of achieving HBV DNA levels below 400 copies/mL was significantly lower with TDF monotherapy in patients with ADV-resistant HBV and high viral load (>107 copies/mL) at baseline compared with those without ADV-resistant HBV.54 Another cohort study also showed that the efficacy of TDF was lower in patients with ADV-resistant HBV than in treatment-naïve patients, especially when they had previously failed to respond to both LAM and ADV.30 On the other hand, a combination of TDF and ETV, which is currently regarded as the strongest combination therapy against HBV, induced a virologic response in up to 90% of patients after a median 6 months of treatment regardless of preexisting ADV- or ETV-resistance.55 However, whether a combination of TDF and ETV exerts better antiviral efficacy than TDF monotherapy in patients with multidrug-resistant HBV could not be identified by these single arm studies.

We recently performed a multicenter trial, in which, patients who had ADV-resistant HBV with serum HBV DNA levels >60 IU/mL were randomized to receive TDF (300 mg/day) monotherapy (n=50) or TDF and ETV (1 mg/day) combination therapy (TDF/ETV, n=52) for 48 weeks. All patients had ADV-resistant HBV mutations; rtA181V/T and/or rtN236T. The proportion of patients with HBV DNA <15 IU/mL was not significantly different between the TDF-TDF and TDF/ETV-TDF groups at week 48 (62% vs 63.5%, p=0.88) and at week 96 (64% vs 63.5%, p=0.96). The proportion of patients who achieved HBV DNA levels <60 IU/mL at week 48 was 74% and 78.8% for the TDF-TDF and TDF/ETV-TDF groups, respectively (p=0.56) (Fig. 5). Virologic breakthrough occurred in one patient on TDF-TDF and two patients on TDF/ETV-TDF over 96 weeks; all were attributed to poor drug adherence. At week 96, five and two patients in the TDF-TDF and TDF/ETV-TDF groups, respectively, retained some of their baseline resistance mutations (p=0.44). None developed additional resistance mutations. Safety profiles were comparable in the two groups. The results suggest that TDF monotherapy may be a treatment option for patients with ADV-resistant HBV. However, in a subgroup of patients who had double ADV-resistance mutations, i.e., both rtA181T/V and rtN236T, the decrease in serum HBV DNA levels tended to be less in the TDF group than in the TDF/ETV-TDF group. Thus, TDF plus ETV combination therapy might be more beneficial than TDF monotherapy in patients who had double ADV-resistance mutations (both rtA181T/V and rtN236T).

CONCLUSIONS

Go to

The primary goal of therapy for CHB is to prevent liver disease progression, and seroclearance or seroconversion of hepatitis B surface antigen (HBsAg) is regarded as an optimal endpoint of treatment.56 However, HBsAg seroclearance occurs very rarely with NUC treatment.56 Long-term HBV DNA and HBsAg level kinetics in patients with CHB treated with potent NUCs showed that HBsAg clearance is unlikely to occur during the patient’s lifetime, even if HBV replication is well controlled.57 Thus, long-term, almost indefinite, NUC treatment is required for the majority of patients.

In patients with drug-resistant HBV, a combination of TDF and ETV would be potentially safer to prevent the emergence of resistance to TDF.58 However, long-term tolerance data are lacking and cost may be an issue for this combination. Considering a comparable antiviral efficacy, extremely low risk of TDF-resistance, lower cost, and potentially better safety profile, TDF monotherapy would be a reasonable option for the treatment of ETV-resistant patients. In fact, TDF monotherapy is now being incorporated as a primary recommendation for the treatment of patients with drug-resistant HBV in many recent practice guidelines (Table 2).24,59–62 However, the rates of virologic response in multidrug-resistant patients seem to be lower compared to those reported in previous clinical trials of TDF in treatment-naïve, LAM-resistant, or ADV-refractory patients.27,29,63 Because the combination of TDF and ETV does not seem to further increase the rate of virologic response, a more potent antiviral agent may be required for patients with HBV mutants resistant to multiple drugs including ADV.

ACKNOWLEDGEMENTS

Go to

This study was supported by grants from the Korean National Health Clinical Research (NHCR) project, Ministry of Health & Welfare, Republic of Korea (HC15C3380); the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI14C1061); and the Proteogenomic Research Program through the National Research Foundation (NRF-2015M3C9A1044530) of Korea funded by the Korea government.

Figures

Go to
Fig. 1.Cumulative incidence of hepatitis B virus resistance in pivotal trials. Adapted from EASL clinical practice guidelines. J Hepatol 2012;57:167–185.
Fig. 2.Evolution of drug-resistant hepatitis B virus. Adapted from Bartholomeusz A, et al. Semin Liver Dis 2006;26:162–170.64; Fournier C, et al. Clin Liver Dis 2007;11:869–892.65

LAM, lamivudine; LdT, telbivudine; CLV, clevudine; ETV, entecavir; ADV, adefovir dipivoxil; W, wild type HBV strain; R, resistant HBV strain.

Fig. 3.Virologic response (hepatitis B virus [HBV] DNA <60 IU/mL) by tenofovir disoproxil fumarate (TDF) monotherapy versus TDF and emtricitabine combination therapy in lamivudine-resistant patients with chronic hepatitis B in a randomized double-blind controlled trial. Intention-to-treat population shown. Adapted from Fung S, et al. Gastroenterology 2014;146:980–988.e1, with permission from El-sevier.29

FTC, emtricitabine.

Fig. 4.Virologic response (hepatitis B virus [HBV] DNA <60 IU/mL) by tenofovir disoproxil fumarate (TDF) monotherapy versus TDF and entecavir (ETV) combination therapy in ETV-resistant patients with chronic hepatitis B in a randomized controlled trial. Intention-to-treat population shown. Adapted from Lim YS, et al. Gut 2016;65:852–860.
Fig. 5.Virologic response (hepatitis B virus [HBV] DNA <60 IU/mL) by tenofovir disoproxil fumarate (TDF) monotherapy versus TDF and entecavir (ETV) combination therapy in adefovir-resistant patients with chronic hepatitis B in a randomized controlled trial. Intention-to-treat population shown. Adapted from Lim YS, et al. Gut 2016;65:1042–1051.

Tables

Go to

Summary of In Vitro Cross-Resistance for Hepatitis B Virus Variants

HBV variantLamivudineEntecavirAdefovirTenofovir
Wild-typeSSSS
M204V/IRIIS
L180M+M204VRIIS
A181T/VRSRS
N236TSSRI
A181T/V+N236TRSRI
L180M+M204V/I±T184RRSS
L180M+M204V/I±S202RRSS
L180M+M204V/I±I169T±M250RRSS

Summary of Recommendations by Practice Guidelines for Patients with Drug-Resistant Hepatitis B Virus

Resistance toAASLD 2016WHO 2015APASL 2015KASL 2015EASL 2012
Primary recommendations
 LamivudineTenofovirTenofovirTenofovirTenofovir or tenofovir+nucleoside analogueTenofovir
 EntecavirTenofovirTenofovirTenofovirTenofovir or tenofovir+entecavirTenofovir or tenofovir+entecavir
 Adefovir (no lamivudine exposure)EntecavirTenofovirEntecavir or tenofovirTenofovir or tenofovir+entecavirEntecavir or tenofovir
 MultidrugTenofovirTenofovirTenofovir+entecavirTenofovir or tenofovir+entecavirTenofovir+nucleoside analogue
Secondary recommendations
 LamivudineTenofovir+lamivudineAdefovir+lamivudineAdefovir+nucleoside analogue or pegylated interferonAdefovir+lamivudine
 EntecavirTenofovir+entecavirAdefovir+entecavirAdefovir+entecavirAdefovir+entecavir
 Adefovir (no lamivudine exposure)Adefovir+entecavirTenofovir+lamivudineTenofovir+nucleoside analogue or adefovir+entecavirTenofovir
 MultidrugTenofovir+entecavirPegylated interferonTenofovir+nucleoside analogue or adefovir+entecavir

References

Go to
  1. Chen, CJ, Yang, HI, and Su, J (2006). Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 295, 65-73.
    Pubmed CrossRef
  2. Iloeje, UH, Yang, HI, and Su, J (2006). Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 130, 678-686.
    Pubmed CrossRef
  3. Liaw, YF, Sung, JJ, and Chow, WC (2004). Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 351, 1521-1531.
    Pubmed CrossRef
  4. Gordon, SC, Lamerato, LE, and Rupp, LB (2014). Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol. 12, 885-893.
    CrossRef
  5. Eun, JR, Lee, HJ, Kim, TN, and Lee, KS (2010). Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol. 53, 118-125.
    Pubmed CrossRef
  6. Papatheodoridis, GV, Dimou, E, and Dimakopoulos, K (2005). Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology. 42, 121-129.
    Pubmed CrossRef
  7. Yuen, MF, Seto, WK, and Chow, DH (2007). Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther. 12, 1295-1303.
  8. Hosaka, T, Suzuki, F, and Kobayashi, M (2013). Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 58, 98-107.
    CrossRef
  9. Wong, GL, Chan, HL, and Mak, CW (2013). Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 58, 1537-1547.
    Pubmed CrossRef
  10. Lim, YS, Han, S, Heo, NY, Shim, JH, Lee, HC, and Suh, DJ (2014). Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology. 147, 152-161.
    Pubmed CrossRef
  11. Wu, CY, Lin, JT, and Ho, HJ (2014). Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 147, 143-151.e5.
    Pubmed CrossRef
  12. European Association for the Study of the Liver (2009). EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 50, 227-242.
    CrossRef
  13. Keeffe, EB, Dieterich, DT, and Han, SH (2008). A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 6, 1315-1341.
    Pubmed CrossRef
  14. Lok, AS, and McMahon, BJ (2009). Chronic hepatitis B: update 2009. Hepatology. 50, 661-662.
    Pubmed CrossRef
  15. Chang, TT, Lai, CL, and Kew Yoon, S (2010). Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 51, 422-430.
    Pubmed CrossRef
  16. Kitrinos, KM, Corsa, A, and Liu, Y (2014). No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 59, 434-442.
    CrossRef
  17. Zoulim, F, and Locarnini, S (2012). Management of treatment failure in chronic hepatitis B. J Hepatol. 56, S112-S122.
    Pubmed CrossRef
  18. Yim, HJ, Hussain, M, Liu, Y, Wong, SN, Fung, SK, and Lok, AS (2006). Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 44, 703-712.
    Pubmed CrossRef
  19. Fung, SK, Chae, HB, and Fontana, RJ (2006). Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 44, 283-290.
    CrossRef
  20. Lee, YS, Suh, DJ, and Lim, YS (2006). Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 43, 1385-1391.
    Pubmed CrossRef
  21. Yeon, JE, Yoo, W, and Hong, SP (2006). Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut. 55, 1488-1495.
    Pubmed KoreaMed CrossRef
  22. Tenney, DJ, Rose, RE, and Baldick, CJ (2007). Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 51, 902-911.
    KoreaMed CrossRef
  23. Tenney, DJ, Rose, RE, and Baldick, CJ (2009). Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 49, 1503-1514.
    Pubmed CrossRef
  24. European Association for the Study of the Liver (2012). EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 57, 167-185.
    Pubmed CrossRef
  25. Korean Association for the Study of the Liver (2012). KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol. 18, 109-162.
    Pubmed KoreaMed CrossRef
  26. Liaw, YF, Kao, JH, and Piratvisuth, T (2012). Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 6, 531-561.
    Pubmed CrossRef
  27. Berg, T, Marcellin, P, and Zoulim, F (2010). Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology. 139, 1207-1217.
    Pubmed CrossRef
  28. Berg, T, Zoulim, F, and Moeller, B (2014). Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol. 60, 715-722.
    CrossRef
  29. Fung, S, Kwan, P, and Fabri, M (2014). Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 146, 980-988.e1.
    CrossRef
  30. Patterson, SJ, George, J, and Strasser, SI (2011). Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. 60, 247-254.
    CrossRef
  31. Lim, YS, Byun, KS, and Yoo, BC (2016). Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut. 65, 852-860.
    CrossRef
  32. Lim, YS, Yoo, BC, and Byun, KS (2016). Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut. 65, 1042-1051.
    CrossRef
  33. Peters, MG, Hann, HW, and Martin, P (2004). Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 126, 91-101.
    CrossRef
  34. Liaw, YF, Leung, N, and Kao, JH (2008). Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2, 263-283.
    CrossRef
  35. Rapti, I, Dimou, E, Mitsoula, P, and Hadziyannis, SJ (2007). Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 45, 307-313.
    Pubmed CrossRef
  36. Lampertico, P, Viganò, M, Manenti, E, Iavarone, M, Sablon, E, and Colombo, M (2007). Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 133, 1445-1451.
    Pubmed CrossRef
  37. Corsa, AC, Liu, Y, and Flaherty, JF (2014). No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin Gastroenterol Hepatol. 12, 2106-2112.e1.
    Pubmed CrossRef
  38. Chang, TT, Gish, RG, and Hadziyannis, SJ (2005). A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 129, 1198-1209.
    Pubmed CrossRef
  39. Sherman, M, Yurdaydin, C, and Sollano, J (2006). Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 130, 2039-2049.
    Pubmed CrossRef
  40. Tenney, DJ, Levine, SM, and Rose, RE (2004). Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 48, 3498-3507.
    Pubmed KoreaMed CrossRef
  41. Villet, S, Ollivet, A, and Pichoud, C (2007). Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol. 46, 531-538.
    Pubmed CrossRef
  42. Pan, CQ, Hu, KQ, Yu, AS, Chen, W, Bunchorntavakul, C, and Reddy, KR (2012). Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hepat. 19, 213-219.
    Pubmed CrossRef
  43. Yip, B, Chaung, K, and Wong, CR (2012). Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders. Dig Dis Sci. 57, 3011-3016.
    Pubmed CrossRef
  44. Leemans, WF, Niesters, HG, van der Eijk, AA, Janssen, HL, Schalm, SW, and de Man, RA (2008). Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. Eur J Gastroenterol Hepatol. 20, 773-777.
    Pubmed CrossRef
  45. Zoulim, F, Jablkowski, MS, and Diculescu, M (2014). The safety and efficacy of entecavir and tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure: week 96 results of the ENTEBE study. Hepatology. 60, 314A-315A.
  46. Villet, S, Pichoud, C, Villeneuve, JP, Trépo, C, and Zoulim, F (2006). Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology. 131, 1253-1261.
    Pubmed CrossRef
  47. Villeneuve, JP, Durantel, D, and Durantel, S (2003). Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol. 39, 1085-1089.
    Pubmed CrossRef
  48. Angus, P, Vaughan, R, and Xiong, S (2003). Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 125, 292-297.
    Pubmed CrossRef
  49. Heo, NY, Lim, YS, Lee, HC, Chung, YH, Lee, YS, and Suh, DJ (2010). Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol. 53, 449-454.
    Pubmed CrossRef
  50. Shim, JH, Suh, DJ, and Kim, KM (2009). Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology. 50, 1064-1071.
    Pubmed CrossRef
  51. Brunelle, MN, Jacquard, AC, and Pichoud, C (2005). Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology. 41, 1391-1398.
    Pubmed CrossRef
  52. Villet, S, Pichoud, C, and Billioud, G (2008). Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol. 48, 747-755.
    Pubmed CrossRef
  53. Qi, X, Xiong, S, Yang, H, Miller, M, and Delaney, WE (2007). In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 12, 355-362.
    Pubmed
  54. van Bömmel, F, de Man, RA, and Wedemeyer, H (2010). Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 51, 73-80.
    CrossRef
  55. Petersen, J, Ratziu, V, and Buti, M (2012). Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol. 56, 520-526.
    CrossRef
  56. Kim, GA, Lim, YS, and An, J (2014). HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 63, 1325-1332.
    CrossRef
  57. Chevaliez, S, Hézode, C, Bahrami, S, Grare, M, and Pawlotsky, JM (2013). Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol. 58, 676-683.
    CrossRef
  58. Pawlotsky, JM (2012). Is hepatitis virus resistance to antiviral drugs a threat?. Gastroenterology. 142, 1369-1372.
    Pubmed CrossRef
  59. Terrault, NA, Bzowej, NH, and Chang, KM (2016). AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 63, 261-283.
    CrossRef
  60. World Health Organization (2015). Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization
  61. Sarin, SK, Kumar, M, and Lau, GK (2016). Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 10, 1-98.
    KoreaMed CrossRef
  62. Korean Association for the Study of Liver (2015). KASL clinical practice guidelines: management of chronic hepatitis B. Seoul: Korean Association for the Study of Liver
  63. Marcellin, P, Heathcote, EJ, and Buti, M (2008). Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 359, 2442-2455.
    Pubmed CrossRef
  64. Bartholomeusz, A, and Locarnini, SA (2006). Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis. 26, 162-170.
    Pubmed CrossRef
  65. Fournier, C, and Zoulim, F (2007). Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis. 11, Array-892.
    Pubmed CrossRef

Article

Review

Gut and Liver 2017; 11(2): 189-195

Published online March 15, 2017 https://doi.org/10.5009/gnl15562

Copyright © Gut and Liver.

Management of Antiviral Resistance in Chronic Hepatitis B

Young-Suk Lim

Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Correspondence to:Young-Suk Lim, Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea, Tel: +82-2-3010-5933, Fax: +82-2-485-5782, E-mail: limys@amc.seoul.kr

Received: November 2, 2015; Accepted: January 17, 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression. Hepatitis B surface antigen (HBsAg) seroclearance or seroconversion is regarded as an optimal endpoint to discontinue treatment. However, HBsAg seroclearance occurs very rarely with nucleos(t)ide analog (NUC) treatment, and long-term, almost indefinite, NUC treatment is required for the majority of patients. In patients with drug-resistant hepatitis B virus (HBV), a combination of tenofovir disoproxil fumarate (TDF) and entecavir (ETV), which is currently regarded as the strongest combination therapy against HBV, would be potentially safe to prevent the emergence of additional HBV resistance mutations. However, long-term tolerance data are lacking, and cost may be an issue for combination therapies. Several recent, well-designed, randomized controlled trials have shown that TDF mono-therapy provides similar antiviral efficacy compared with the combination of TDF and ETV. Furthermore, no additional HBV resistance mutations emerged during TDF monotherapy for up to 96 weeks. Considering a comparable antiviral efficacy, extremely low risk of TDF-resistance, lower cost, and better safety potential, TDF monotherapy would be a reasonable choice for the treatment of drug-resistant patients with CHB.

Keywords: Adefovir, Entecavir, Lamivudine, Monotherapy, Tenofovir

INTRODUCTION

High serum hepatitis B virus (HBV) DNA levels are an independent risk factor for disease progression to cirrhosis and hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB).1,2 By contrast, reducing HBV DNA concentrations to very low or undetectable levels through long-term nucleos(t)ide analogue (NUC) therapy is associated with reduced risk of mortality and/or HCC.3–11

Over the past two decades, treatment of CHB has greatly improved with the availability of NUCs, including lamivudine (LAM), adefovir (ADV), entecavir (ETV), telbivudine, and tenofovir, which target particular sites of viral polymerases.12–14 Particularly, with the availability of potent NUCs, such as tenofovir disoproxil fumarate (TDF) and ETV, suppression of serum HBV DNA to levels undetectable by polymerase chain reaction assays is achievable in most NUC treatment-naïve patients in the absence of drug-resistant HBV mutants (Fig. 1).15,16 However, many patients worldwide have developed drug-resistance from the widespread use of less potent NUCs, such as LAM or ADV, which have a low genetic barrier to resistance. Patients with persistent drug-resistant HBV viremia are more likely to suffer hepatitis flares, disease progression, and to die than those without drug-resistant HBV.3,6

MECHANISM OF ANTIVIRAL DRUG RESISTANCE

Nucleoside- and nucleotide-analogues selectively target HBV DNA polymerase, resulting in premature chain termination of viral replication. Drug-resistant strains of HBV have signature mutations in the reverse transcriptase domains of the viral polymerase gene (Table 1). Resistance mutations alter the interaction between HBV polymerase and drug, which interfere the inhibitory effect of drug on viral polymerase. After emergence of primary resistance mutations, compensatory mutations that restore replication capacity may arise (Fig. 2), as well as secondary resistance mutations that increase drug resistance when they accumulate on the same viral genome.

Once antiviral-resistant HBV mutants have been selected, they are persistently retained in the virus population even if treatment is stopped, and exerts cross-resistance to the next sequential monotherapy (Fig. 2).14,17,18 For example, ADV-resistant mutations emerge more frequently during ADV monotherapy in LAM-resistant than in treatment-naïve patients.19–21 The rate of ETV resistance increases up to 51% after 5 years of ETV treatment in patients with LAM-resistant HBV, which is in striking contrast to a 1.2% resistance rate in NUC-naïve patients.22,23 Thus, combination therapy with a nucleoside analogue (LAM, telbivudine, or ETV) and a nucleotide analogue (ADV or TDF) has generally been recommended for the treatment of patients harboring drug-resistant HBV.14,24–26 However, several recent studies including ours have suggested that TDF monotherapy is efficacious in patients with LAM-resistant, ETV-resistant, or ADV-resistant HBV.27–32

MANAGEMENT OF RESISTANCE TO LAMIVUDINE

For LAM-resistant patients, a combination of ADV and LAM showed no greater antiviral efficacy than ADV monotherapy.33 Nonetheless, ADV and LAM combination therapy had been recommended for these patients to prevent additional emergence of ADV-resistant HBV mutants.14,20,24,25,34–36

However, the situation is clearly different if TDF, that has about 30 times higher anti-HBV potency than ADV, is used instead of ADV. Treatment responses to TDF and LAM combination therapy would likely be mediated by TDF alone, since LAM may have no or minimal antiviral efficacy in the presence of LAM-resistant HBV mutants. With this combination, continued LAM treatment would likely only help prevent the development of TDF-resistance mutations, rather than increasing antiviral potency. Therefore, if there is minimal risk of TDF-resistance,16,37 the addition of LAM to TDF would theoretically provide little benefit. The hypothesis was actually proven by a recent randomized double-blind controlled trial.29 The study showed that TDF monotherapy was highly efficacious in patients with LAM-resistant HBV, which was comparable to the combination of TDF and emtricitabine, without emergence of additional resistance mutations to TDF throughout 96 weeks of treatment (Fig. 3).29,37 Entricitabine is an unapproved nucleoside analogue which has very similar anti-HBV potency and barrier to resistance development as LAM. Thus, the study results indicate that adding LAM to TDF would not provide additional antiviral benefit, and that TDF monotherapy is safe and efficacious to patients with LAM-resistant HBV.

MANAGEMENT OF RESISTANCE TO LAM AND ETV

In patients with pre-existing LAM-resistance, the rate of ETV resistance increases up to 51% after 5 years of ETV treatment, which is in striking contrast to a 1.2% resistance rate in NUC-naïve patients.22,23 In addition, ETV monotherapy was suboptimal in suppressing HBV replication in patients with LAM-resistant HBV, with an unacceptably low virologic response rate (22%) seen at 12 months.38,39 This difference is because the ETV resistance barrier is lowered by the initial selection of the LAM-resistant HBV mutation, rtM204V/I.40In vitro studies have shown that susceptibility to ETV is decreases by 10- to 250-fold when one of the ETV resistance-associated substitutions at rtT184, rtS202, or rtM250 is present in combination with rtM204V/I, and by >500-fold when two or more of these mutations are present.22,40

In vitro studies suggest that ETV-resistant HBV mutants are susceptible to TDF.17,41 These in vitro studies showed that HBV strains harboring the ETV resistance-associated substitutions, rtM204V/I, rtT184, rtS202, and/or rtM250, exhibit no cross-resistance to tenofovir.17,41 Several case reports and retrospective cohort studies also showed the clinical efficacy of TDF in ETV-resistant or ETV-refractory patients.42–44

In our recent multicenter randomized trial, patients who had HBV with ETV resistance-associated mutations and serum HBV DNA concentrations >60 IU/mL were randomized to receive TDF (300 mg/day) monotherapy (n=45) or TDF and ETV (1 mg/day) combination therapy (n=45). At week 48, the proportion of patients with HBV DNA <15 IU/mL, the primary efficacy endpoint, was not significantly different between the TDF and TDF+ETV groups (71% vs 73%, p=0.81). The proportion of patients who achieved HBV DNA levels <60 IU/mL at week 48 was 82% and 89% for the TDF and TDF+ETV groups, respectively (p=0.55) (Fig. 4). The mean change in HBV DNA levels from baseline was not significantly different between groups (−3.65 log10 IU/mL vs −3.77 log10 IU/mL, p=0.69). Virologic breakthrough occurred in one patient on TDF, which was attributed to poor drug adherence. At week 48, six and three patients in the TDF and TDF+ETV groups, respectively, retained their baseline resistance mutations (p>0.99). None developed additional resistance mutations. Safety profiles were comparable in the two groups. The rate of virologic response by TDF monotherapy in our study was similar with that of a recent single arm trial with TDF+ETV in CHB patients with previous NUC treatment failure (85% had HBV DNA <50 IU/mL at week 96).45 These results support the view that TDF monotherapy may be a treatment option for patients with ETV-resistant HBV.

MANAGEMENT OF RESISTANCE TO LAM AND ADV

In vitro clonal analyses showed that multidrug-resistance mutations usually reside in the same viral genome,18,46 and antiviral sensitivities revealed that replicating clones with LAM- and ADV-associated mutations had >50-fold reduced susceptibility to combination of LAM and ADV.47,48 In fact, our previous cohort study demonstrated that, in patients with HBV resistant to LAM and ADV, combination therapy with these two drugs was not effective and was even inferior to ETV monotherapy in suppressing HBV DNA.49 However, the response to ETV monotherapy was not optimal. We demonstrated that ETV was far less effective in patients refractory to both LAM and ADV than in those with LAM mono-resistance.50

In vitro studies have shown that HBV strains expressing the ADV resistance-associated substitutions, rtA181T/V and/or rtN236T, demonstrate reduced susceptibility to tenofovir, ranging from 2.9- to 10-fold of that of the wild-type virus.46,51–53 Several cohort studies also showed reduced TDF efficacy in patients with ADV-resistant HBV.30,54 An European cohort study showed that, the probability of achieving HBV DNA levels below 400 copies/mL was significantly lower with TDF monotherapy in patients with ADV-resistant HBV and high viral load (>107 copies/mL) at baseline compared with those without ADV-resistant HBV.54 Another cohort study also showed that the efficacy of TDF was lower in patients with ADV-resistant HBV than in treatment-naïve patients, especially when they had previously failed to respond to both LAM and ADV.30 On the other hand, a combination of TDF and ETV, which is currently regarded as the strongest combination therapy against HBV, induced a virologic response in up to 90% of patients after a median 6 months of treatment regardless of preexisting ADV- or ETV-resistance.55 However, whether a combination of TDF and ETV exerts better antiviral efficacy than TDF monotherapy in patients with multidrug-resistant HBV could not be identified by these single arm studies.

We recently performed a multicenter trial, in which, patients who had ADV-resistant HBV with serum HBV DNA levels >60 IU/mL were randomized to receive TDF (300 mg/day) monotherapy (n=50) or TDF and ETV (1 mg/day) combination therapy (TDF/ETV, n=52) for 48 weeks. All patients had ADV-resistant HBV mutations; rtA181V/T and/or rtN236T. The proportion of patients with HBV DNA <15 IU/mL was not significantly different between the TDF-TDF and TDF/ETV-TDF groups at week 48 (62% vs 63.5%, p=0.88) and at week 96 (64% vs 63.5%, p=0.96). The proportion of patients who achieved HBV DNA levels <60 IU/mL at week 48 was 74% and 78.8% for the TDF-TDF and TDF/ETV-TDF groups, respectively (p=0.56) (Fig. 5). Virologic breakthrough occurred in one patient on TDF-TDF and two patients on TDF/ETV-TDF over 96 weeks; all were attributed to poor drug adherence. At week 96, five and two patients in the TDF-TDF and TDF/ETV-TDF groups, respectively, retained some of their baseline resistance mutations (p=0.44). None developed additional resistance mutations. Safety profiles were comparable in the two groups. The results suggest that TDF monotherapy may be a treatment option for patients with ADV-resistant HBV. However, in a subgroup of patients who had double ADV-resistance mutations, i.e., both rtA181T/V and rtN236T, the decrease in serum HBV DNA levels tended to be less in the TDF group than in the TDF/ETV-TDF group. Thus, TDF plus ETV combination therapy might be more beneficial than TDF monotherapy in patients who had double ADV-resistance mutations (both rtA181T/V and rtN236T).

CONCLUSIONS

The primary goal of therapy for CHB is to prevent liver disease progression, and seroclearance or seroconversion of hepatitis B surface antigen (HBsAg) is regarded as an optimal endpoint of treatment.56 However, HBsAg seroclearance occurs very rarely with NUC treatment.56 Long-term HBV DNA and HBsAg level kinetics in patients with CHB treated with potent NUCs showed that HBsAg clearance is unlikely to occur during the patient’s lifetime, even if HBV replication is well controlled.57 Thus, long-term, almost indefinite, NUC treatment is required for the majority of patients.

In patients with drug-resistant HBV, a combination of TDF and ETV would be potentially safer to prevent the emergence of resistance to TDF.58 However, long-term tolerance data are lacking and cost may be an issue for this combination. Considering a comparable antiviral efficacy, extremely low risk of TDF-resistance, lower cost, and potentially better safety profile, TDF monotherapy would be a reasonable option for the treatment of ETV-resistant patients. In fact, TDF monotherapy is now being incorporated as a primary recommendation for the treatment of patients with drug-resistant HBV in many recent practice guidelines (Table 2).24,59–62 However, the rates of virologic response in multidrug-resistant patients seem to be lower compared to those reported in previous clinical trials of TDF in treatment-naïve, LAM-resistant, or ADV-refractory patients.27,29,63 Because the combination of TDF and ETV does not seem to further increase the rate of virologic response, a more potent antiviral agent may be required for patients with HBV mutants resistant to multiple drugs including ADV.

ACKNOWLEDGEMENTS

This study was supported by grants from the Korean National Health Clinical Research (NHCR) project, Ministry of Health & Welfare, Republic of Korea (HC15C3380); the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI14C1061); and the Proteogenomic Research Program through the National Research Foundation (NRF-2015M3C9A1044530) of Korea funded by the Korea government.

Fig 1.

Download
Figure 1.Cumulative incidence of hepatitis B virus resistance in pivotal trials. Adapted from EASL clinical practice guidelines. J Hepatol 2012;57:167–185.
Gut and Liver 2017; 11: 189-195https://doi.org/10.5009/gnl15562

Fig 2.

Download
Figure 2.Evolution of drug-resistant hepatitis B virus. Adapted from Bartholomeusz A, et al. Semin Liver Dis 2006;26:162–170.64; Fournier C, et al. Clin Liver Dis 2007;11:869–892.65

LAM, lamivudine; LdT, telbivudine; CLV, clevudine; ETV, entecavir; ADV, adefovir dipivoxil; W, wild type HBV strain; R, resistant HBV strain.

Gut and Liver 2017; 11: 189-195https://doi.org/10.5009/gnl15562

Fig 3.

Download
Figure 3.Virologic response (hepatitis B virus [HBV] DNA <60 IU/mL) by tenofovir disoproxil fumarate (TDF) monotherapy versus TDF and emtricitabine combination therapy in lamivudine-resistant patients with chronic hepatitis B in a randomized double-blind controlled trial. Intention-to-treat population shown. Adapted from Fung S, et al. Gastroenterology 2014;146:980–988.e1, with permission from El-sevier.29

FTC, emtricitabine.

Gut and Liver 2017; 11: 189-195https://doi.org/10.5009/gnl15562

Fig 4.

Download
Figure 4.Virologic response (hepatitis B virus [HBV] DNA <60 IU/mL) by tenofovir disoproxil fumarate (TDF) monotherapy versus TDF and entecavir (ETV) combination therapy in ETV-resistant patients with chronic hepatitis B in a randomized controlled trial. Intention-to-treat population shown. Adapted from Lim YS, et al. Gut 2016;65:852–860.
Gut and Liver 2017; 11: 189-195https://doi.org/10.5009/gnl15562

Fig 5.

Download
Figure 5.Virologic response (hepatitis B virus [HBV] DNA <60 IU/mL) by tenofovir disoproxil fumarate (TDF) monotherapy versus TDF and entecavir (ETV) combination therapy in adefovir-resistant patients with chronic hepatitis B in a randomized controlled trial. Intention-to-treat population shown. Adapted from Lim YS, et al. Gut 2016;65:1042–1051.
Gut and Liver 2017; 11: 189-195https://doi.org/10.5009/gnl15562

Table 1 Summary of In Vitro Cross-Resistance for Hepatitis B Virus Variants

HBV variantLamivudineEntecavirAdefovirTenofovir
Wild-typeSSSS
M204V/IRIIS
L180M+M204VRIIS
A181T/VRSRS
N236TSSRI
A181T/V+N236TRSRI
L180M+M204V/I±T184RRSS
L180M+M204V/I±S202RRSS
L180M+M204V/I±I169T±M250RRSS

HBV, hepatitis B virus; S, sensitive; I, intermediate/reduced susceptibility; R, resistant.

Table 2 Summary of Recommendations by Practice Guidelines for Patients with Drug-Resistant Hepatitis B Virus

Resistance toAASLD 2016WHO 2015APASL 2015KASL 2015EASL 2012
Primary recommendations
 LamivudineTenofovirTenofovirTenofovirTenofovir or tenofovir+nucleoside analogueTenofovir
 EntecavirTenofovirTenofovirTenofovirTenofovir or tenofovir+entecavirTenofovir or tenofovir+entecavir
 Adefovir (no lamivudine exposure)EntecavirTenofovirEntecavir or tenofovirTenofovir or tenofovir+entecavirEntecavir or tenofovir
 MultidrugTenofovirTenofovirTenofovir+entecavirTenofovir or tenofovir+entecavirTenofovir+nucleoside analogue
Secondary recommendations
 LamivudineTenofovir+lamivudineAdefovir+lamivudineAdefovir+nucleoside analogue or pegylated interferonAdefovir+lamivudine
 EntecavirTenofovir+entecavirAdefovir+entecavirAdefovir+entecavirAdefovir+entecavir
 Adefovir (no lamivudine exposure)Adefovir+entecavirTenofovir+lamivudineTenofovir+nucleoside analogue or adefovir+entecavirTenofovir
 MultidrugTenofovir+entecavirPegylated interferonTenofovir+nucleoside analogue or adefovir+entecavir

AASLD, American Association for the Study of Liver; WHO, World Health Organization; APASL, Asian-Pacific Association for the Study of Liver; KASL, Korean Association for the Study of Liver; EASL, European Association for the Study of Liver.

References

  1. Chen, CJ, Yang, HI, and Su, J (2006). Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 295, 65-73.
    Pubmed CrossRef
  2. Iloeje, UH, Yang, HI, and Su, J (2006). Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 130, 678-686.
    Pubmed CrossRef
  3. Liaw, YF, Sung, JJ, and Chow, WC (2004). Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 351, 1521-1531.
    Pubmed CrossRef
  4. Gordon, SC, Lamerato, LE, and Rupp, LB (2014). Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol. 12, 885-893.
    CrossRef
  5. Eun, JR, Lee, HJ, Kim, TN, and Lee, KS (2010). Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol. 53, 118-125.
    Pubmed CrossRef
  6. Papatheodoridis, GV, Dimou, E, and Dimakopoulos, K (2005). Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology. 42, 121-129.
    Pubmed CrossRef
  7. Yuen, MF, Seto, WK, and Chow, DH (2007). Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther. 12, 1295-1303.
  8. Hosaka, T, Suzuki, F, and Kobayashi, M (2013). Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 58, 98-107.
    CrossRef
  9. Wong, GL, Chan, HL, and Mak, CW (2013). Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 58, 1537-1547.
    Pubmed CrossRef
  10. Lim, YS, Han, S, Heo, NY, Shim, JH, Lee, HC, and Suh, DJ (2014). Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology. 147, 152-161.
    Pubmed CrossRef
  11. Wu, CY, Lin, JT, and Ho, HJ (2014). Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 147, 143-151.e5.
    Pubmed CrossRef
  12. European Association for the Study of the Liver (2009). EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 50, 227-242.
    CrossRef
  13. Keeffe, EB, Dieterich, DT, and Han, SH (2008). A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 6, 1315-1341.
    Pubmed CrossRef
  14. Lok, AS, and McMahon, BJ (2009). Chronic hepatitis B: update 2009. Hepatology. 50, 661-662.
    Pubmed CrossRef
  15. Chang, TT, Lai, CL, and Kew Yoon, S (2010). Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 51, 422-430.
    Pubmed CrossRef
  16. Kitrinos, KM, Corsa, A, and Liu, Y (2014). No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 59, 434-442.
    CrossRef
  17. Zoulim, F, and Locarnini, S (2012). Management of treatment failure in chronic hepatitis B. J Hepatol. 56, S112-S122.
    Pubmed CrossRef
  18. Yim, HJ, Hussain, M, Liu, Y, Wong, SN, Fung, SK, and Lok, AS (2006). Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 44, 703-712.
    Pubmed CrossRef
  19. Fung, SK, Chae, HB, and Fontana, RJ (2006). Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 44, 283-290.
    CrossRef
  20. Lee, YS, Suh, DJ, and Lim, YS (2006). Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 43, 1385-1391.
    Pubmed CrossRef
  21. Yeon, JE, Yoo, W, and Hong, SP (2006). Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut. 55, 1488-1495.
    Pubmed KoreaMed CrossRef
  22. Tenney, DJ, Rose, RE, and Baldick, CJ (2007). Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 51, 902-911.
    KoreaMed CrossRef
  23. Tenney, DJ, Rose, RE, and Baldick, CJ (2009). Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 49, 1503-1514.
    Pubmed CrossRef
  24. European Association for the Study of the Liver (2012). EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 57, 167-185.
    Pubmed CrossRef
  25. Korean Association for the Study of the Liver (2012). KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol. 18, 109-162.
    Pubmed KoreaMed CrossRef
  26. Liaw, YF, Kao, JH, and Piratvisuth, T (2012). Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 6, 531-561.
    Pubmed CrossRef
  27. Berg, T, Marcellin, P, and Zoulim, F (2010). Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology. 139, 1207-1217.
    Pubmed CrossRef
  28. Berg, T, Zoulim, F, and Moeller, B (2014). Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol. 60, 715-722.
    CrossRef
  29. Fung, S, Kwan, P, and Fabri, M (2014). Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 146, 980-988.e1.
    CrossRef
  30. Patterson, SJ, George, J, and Strasser, SI (2011). Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. 60, 247-254.
    CrossRef
  31. Lim, YS, Byun, KS, and Yoo, BC (2016). Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut. 65, 852-860.
    CrossRef
  32. Lim, YS, Yoo, BC, and Byun, KS (2016). Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut. 65, 1042-1051.
    CrossRef
  33. Peters, MG, Hann, HW, and Martin, P (2004). Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 126, 91-101.
    CrossRef
  34. Liaw, YF, Leung, N, and Kao, JH (2008). Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2, 263-283.
    CrossRef
  35. Rapti, I, Dimou, E, Mitsoula, P, and Hadziyannis, SJ (2007). Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 45, 307-313.
    Pubmed CrossRef
  36. Lampertico, P, Viganò, M, Manenti, E, Iavarone, M, Sablon, E, and Colombo, M (2007). Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 133, 1445-1451.
    Pubmed CrossRef
  37. Corsa, AC, Liu, Y, and Flaherty, JF (2014). No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin Gastroenterol Hepatol. 12, 2106-2112.e1.
    Pubmed CrossRef
  38. Chang, TT, Gish, RG, and Hadziyannis, SJ (2005). A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 129, 1198-1209.
    Pubmed CrossRef
  39. Sherman, M, Yurdaydin, C, and Sollano, J (2006). Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 130, 2039-2049.
    Pubmed CrossRef
  40. Tenney, DJ, Levine, SM, and Rose, RE (2004). Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 48, 3498-3507.
    Pubmed KoreaMed CrossRef
  41. Villet, S, Ollivet, A, and Pichoud, C (2007). Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol. 46, 531-538.
    Pubmed CrossRef
  42. Pan, CQ, Hu, KQ, Yu, AS, Chen, W, Bunchorntavakul, C, and Reddy, KR (2012). Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hepat. 19, 213-219.
    Pubmed CrossRef
  43. Yip, B, Chaung, K, and Wong, CR (2012). Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders. Dig Dis Sci. 57, 3011-3016.
    Pubmed CrossRef
  44. Leemans, WF, Niesters, HG, van der Eijk, AA, Janssen, HL, Schalm, SW, and de Man, RA (2008). Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. Eur J Gastroenterol Hepatol. 20, 773-777.
    Pubmed CrossRef
  45. Zoulim, F, Jablkowski, MS, and Diculescu, M (2014). The safety and efficacy of entecavir and tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure: week 96 results of the ENTEBE study. Hepatology. 60, 314A-315A.
  46. Villet, S, Pichoud, C, Villeneuve, JP, Trépo, C, and Zoulim, F (2006). Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology. 131, 1253-1261.
    Pubmed CrossRef
  47. Villeneuve, JP, Durantel, D, and Durantel, S (2003). Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol. 39, 1085-1089.
    Pubmed CrossRef
  48. Angus, P, Vaughan, R, and Xiong, S (2003). Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 125, 292-297.
    Pubmed CrossRef
  49. Heo, NY, Lim, YS, Lee, HC, Chung, YH, Lee, YS, and Suh, DJ (2010). Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol. 53, 449-454.
    Pubmed CrossRef
  50. Shim, JH, Suh, DJ, and Kim, KM (2009). Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology. 50, 1064-1071.
    Pubmed CrossRef
  51. Brunelle, MN, Jacquard, AC, and Pichoud, C (2005). Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology. 41, 1391-1398.
    Pubmed CrossRef
  52. Villet, S, Pichoud, C, and Billioud, G (2008). Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol. 48, 747-755.
    Pubmed CrossRef
  53. Qi, X, Xiong, S, Yang, H, Miller, M, and Delaney, WE (2007). In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 12, 355-362.
    Pubmed
  54. van Bömmel, F, de Man, RA, and Wedemeyer, H (2010). Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 51, 73-80.
    CrossRef
  55. Petersen, J, Ratziu, V, and Buti, M (2012). Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol. 56, 520-526.
    CrossRef
  56. Kim, GA, Lim, YS, and An, J (2014). HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 63, 1325-1332.
    CrossRef
  57. Chevaliez, S, Hézode, C, Bahrami, S, Grare, M, and Pawlotsky, JM (2013). Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol. 58, 676-683.
    CrossRef
  58. Pawlotsky, JM (2012). Is hepatitis virus resistance to antiviral drugs a threat?. Gastroenterology. 142, 1369-1372.
    Pubmed CrossRef
  59. Terrault, NA, Bzowej, NH, and Chang, KM (2016). AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 63, 261-283.
    CrossRef
  60. World Health Organization (2015). Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization
  61. Sarin, SK, Kumar, M, and Lau, GK (2016). Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 10, 1-98.
    KoreaMed CrossRef
  62. Korean Association for the Study of Liver (2015). KASL clinical practice guidelines: management of chronic hepatitis B. Seoul: Korean Association for the Study of Liver
  63. Marcellin, P, Heathcote, EJ, and Buti, M (2008). Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 359, 2442-2455.
    Pubmed CrossRef
  64. Bartholomeusz, A, and Locarnini, SA (2006). Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis. 26, 162-170.
    Pubmed CrossRef
  65. Fournier, C, and Zoulim, F (2007). Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis. 11, Array-892.
    Pubmed CrossRef
Gut and Liver

Vol.16 No.5
September, 2022

Frequency : Quarterly

pISSN 1976-2283
eISSN 2005-1212

qrcode
qrcode

Share this article on :

  • line

Related articles in Gut and Liver

powered by TREND MD

Popular Keywords

Gut and LiverQR code Download
qr-code

Editorial Office